Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Last trade$9.31
Day change-$0.275 (-2.87%)
Day range$9.04 – $10.08
Volume2,339,344
Market cap$1.64B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.64B
Price / earnings
—
Price / book
1.83×
Price / sales
5.42×
EV / sales
4.7×
EV / EBITDA
-7.11×
Profitability
Earnings per share
-$1.08
Return on assets
-16.62%
Return on equity
-20.62%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.3×
Quick ratio
6.3×
Cash ratio
2.71×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$141.82M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VIR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
-$188K
$238.95M
-$29K
$64.07M
$240K
$1.21M
$3.03M
$12.37M
Cost of revenue
$0
$0
$0
$26K
-$11K
$11K
$0
$684K
Gross profit
-$188K
$238.95M
-$29K
$64.04M
$251K
$1.2M
$3.03M
$11.69M
Selling, general and administrative
$24.43M
$30.2M
$23.34M
$23.62M
$22.23M
$22.28M
$23.94M
$26.7M
Research and development
$80.04M
$135.28M
$108.92M
$88.35M
$151.46M
$97.51M
$118.65M
$106.08M
Total operating expenses
$104.47M
$165.48M
$132.26M
$111.97M
$173.69M
$119.62M
$142.58M
$128.84M
Operating income
-$104.66M
$73.47M
-$132.29M
-$47.92M
-$173.44M
-$118.42M
-$139.55M
-$117.15M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$96.4M
$80.26M
-$125.53M
-$43.06M
-$162.97M
-$110.79M
-$120.95M
-$104.68M
Income taxes
-$143K
$179K
$170K
-$137K
$168K
$170K
$16K
-$86K
Net income
-$96.25M
$80.08M
-$125.7M
-$42.92M
-$163.14M
-$110.96M
-$120.97M
-$104.59M
Net income attributable to common shareholders
-$96.25M
$80.08M
-$125.7M
-$42.92M
-$163.14M
-$110.96M
-$120.97M
-$104.59M
EBITDA
-$101.89M
$76.27M
-$129.48M
-$45.02M
-$170.45M
-$115.67M
-$136.69M
-$118.21M
Basic earnings per share
-$0.57
$0.48
-$0.85
-$0.31
-$1.17
-$0.80
-$0.88
-$0.76
Diluted earnings per share
-$0.57
$0.47
-$0.85
-$0.31
-$1.17
-$0.80
-$0.88
-$0.76
Recent news
Company coverage with links to the original publishers.
Vir Biotechnology (VIR) has a mean analyst price target of $21.44, suggesting 75.6% upside potential from its current $12.21 price. The stock has gained 4.4% over the past four weeks, and analysts have recently revised earnings estimates higher, with VIR holding a Zacks Rank #2 (Buy) rating. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as they are often subject to analyst bias and business incentives.
Beam Therapeutics (BEAM) shares surged 15.6% following positive early-stage data for its experimental gene-editing treatment BEAM-301 for glycogen storage disease type Ia. The treatment showed improvements in fasting tolerance and glucose control in six patients, with two patients no longer requiring daily starch supplements. Despite some serious adverse events, the company plans to test higher doses and pursue FDA approval discussions. However, earnings estimate revisions remain unchanged, which may limit sustained momentum.
Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies.
Superstring Capital Management established a new $5.82 million position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026. The investment appears to be a bet on upcoming clinical catalysts rather than current financials, with Vir expecting Phase 3 hepatitis delta data in Q4 2026 and pivotal Phase 3 oncology trials in 2027. Despite being unprofitable, the company has a strong balance sheet with $809.3 million in cash and runway into late 2028.
A new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—are being developed by multiple biotech companies, with over $1.7 billion in dealmaking activity. GT Biopharma's GTB-5550 NK cell engager and Vir Biotechnology's VIR-5500 PSMA-targeted T-cell engager represent leading programs in this emerging therapeutic landscape.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.